A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study

被引:8
|
作者
Qurashi, Inti [1 ]
Chaudhry, Imran B. [2 ,3 ,4 ]
Khoso, Ameer B. [4 ]
Husain, Muhammad Omair [5 ,6 ]
Hafeez, Danish [7 ]
Kiran, Tayyeba [4 ]
Lane, Steven [8 ]
Naqvi, Haider A. [9 ]
Minhas, Fareed A. [10 ]
Nizami, Asad Tamizuddin [10 ]
Razzaque, Bushra [10 ]
Bokhari, Sumira Qambar [11 ]
Yung, Alison R. [12 ,13 ]
Deakin, Bill [14 ]
Husain, Nusrat [2 ,15 ]
机构
[1] Univ Liverpool, Inst Populat Hlth, Liverpool, England
[2] Univ Manchester, Div Psychol & Mental Hlth, Manchester, England
[3] Ziauddin Univ, Dept Psychiat, Karachi, Pakistan
[4] Pakistan Inst Living & Learning, Karachi, Pakistan
[5] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Homerton Univ Hosp, London, England
[8] Univ Liverpool, Inst Translat Med, Liverpool, England
[9] Dow Univ Hlth Sci, Dept Psychiat, Karachi, Pakistan
[10] Rawalpindi Med Univ, Inst Psychiat, Rawalpindi, Pakistan
[11] Serv Inst Med Sci, Dept Psychiat & Behav Sci, Lahore, Pakistan
[12] Univ Melbourne, Ctr Youth Mental Hlth, Parkville, Vic, Australia
[13] Orygen, Parkville, Vic, Australia
[14] Univ Manchester, Sch Biol Sci, Div Neurosci & Expt Psychol, Manchester, England
[15] Mersey Care NHS Fdn Trust, Prescot, England
关键词
Early intervention; Psychosis; Minocycline; Omega-3; At-risk mental state; Inflammation; POLYUNSATURATED FATTY-ACIDS; PSYCHOTIC DISORDERS; YOUNG-PEOPLE; SCHIZOPHRENIA; VERSION; ONSET;
D O I
10.1016/j.bbi.2023.10.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Inflammatory mechanisms are thought to contribute to the onset of psychosis in persons with an at -risk mental state (ARMS). We investigated whether the anti-inflammatory properties of minocycline and omega -3 polyunsaturated fatty acids (omega-3), alone or synergistically, would prevent transition to psychosis in ARMS in a randomised, double-blind, placebo-controlled trial in Pakistan.Methods: 10,173 help-seeking individuals aged 16-35 years were screened using the Prodromal Questionaire-16. Individuals scoring 6 and over were interviewed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) to confirm ARMS. Participants (n = 326) were randomised to minocycline, omega-3, combined minocycline and omega-3 or to double placebo for 6 months. The primary outcome was transition to psychosis at 12 months.Findings: Forty-five (13.8 %) participants transitioned to psychosis. The risk of transition was greater in those randomised to omega-3 alone or in combination with minocycline (17.3.%), compared to 10.4 % in those not exposed to omega-3; a risk-ratio (RR) of 1.67, 95 % CI [0.95, 2.92] p = 0.07. The RR for transitions on mino-cycline vs. no minocycline was 0.86, 95 % CI [0.50, 1.49] p > 0.10. In participants who did not become psychotic, CAARMS and depression symptom scores were reduced at six and twelve months (mean CAARMS difference = 1.43; 95 % CI [0.33, 1.76] p < 0.01 in those exposed to omega-3. Minocycline did not affect CAARMS or depression scores.Interpretation: In keeping with other studies, omega-3 appears to have beneficial effects on ARMS and mood symptom severity but it increased transition to psychosis, which may reflect metabolic or developmental consequences of chronic poor nutrition in the population. Transition to psychosis was too rare to reveal a preventative effect of minocycline but minocycline did not improve symptom severity. ARMS symptom severity and transition to psychosis appear to have distinct pathogeneses which are differentially modulated by omega-3 supplementation.Funding: The study was funded by the Stanley Research Medical Institute.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 50 条
  • [41] The Beyond Ageing Project Phase 2 - a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial
    Nicole L. Cockayne
    Shantel L. Duffy
    Rosalind Bonomally
    Amelia English
    Paul G. Amminger
    Andrew Mackinnon
    Helen M. Christensen
    Sharon L. Naismith
    Ian B. Hickie
    Trials, 16
  • [42] Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Jun, Ji Eun
    Jeong, In Kyung
    Yu, Jae Myung
    Kim, Sung Rae
    Lee, In Kye
    Han, Kyung-Ah
    Choi, Sung Hee
    Kim, Soo-Kyung
    Park, Hyeong Kyu
    Mok, Ji-Oh
    Lee, Yong-ho
    Kwon, Hyuk-Sang
    Kim, So Hun
    Kang, Ho Cheol
    Lee, Sang Ah
    Lee, Chang Beom
    Choi, Kyung Mook
    Her, Sung-Ho
    Shin, Won Yong
    Shin, Mi-Seung
    Ahn, Hyo-Suk
    Kang, Seung Ho
    Cho, Jin-Man
    Jo, Sang-Ho
    Cha, Tae-Joon
    Kim, Seok Yeon
    Won, Kyung Heon
    Kim, Dong-Bin
    Lee, Jae Hyuk
    Lee, Moon-Kyu
    DIABETES & METABOLISM JOURNAL, 2020, 44 (01) : 78 - 90
  • [43] Omega-3 fatty acids in major depressive disorder - A preliminary double-blind, placebo-controlled trial (vol 13, pg 267, 2003)
    Su, KP
    Huang, SY
    Chiu, CC
    Shen, WW
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (02) : 173 - 173
  • [44] AMELIORATION OF SEVERE MIGRAINE WITH OMEGA-3-FATTY-ACIDS - A DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL-TRIAL
    GLUECK, CJ
    MCCARREN, T
    HITZEMANN, R
    ALLEN, C
    HOGG, E
    KLOSS, R
    THOMPSON, B
    YUNKER, R
    GARTSIDE, P
    LAZKARZEWSKI, PM
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1986, 43 (04): : 710 - 710
  • [45] AMELIORATION OF SEVERE MIGRAINE WITH OMEGA-3-FATTY-ACIDS - A DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL-TRIAL
    GLUECK, CJ
    MCCARREN, T
    HITZEMANN, R
    ALLEN, C
    HOGG, E
    KLOSS, R
    THOMPSON, B
    YUNKER, R
    GARTSIDE, P
    LAZKARZEWSKI, PM
    CLINICAL RESEARCH, 1986, 34 (02): : A796 - A796
  • [46] The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial
    Mozurkewich, Ellen L.
    Clinton, Chelsea M.
    Chilimigras, Julie L.
    Hamilton, Susan E.
    Allbaugh, Lucy J.
    Berman, Deborah R.
    Marcus, Sheila M.
    Romero, Vivian C.
    Treadwell, Marjorie C.
    Keeton, Kristie L.
    Vahratian, Anjel M.
    Schrader, Ronald M.
    Ren, Jianwei
    Djuric, Zora
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (04) : 313.e1 - 313.e9
  • [47] The Mothers, Omega-3 & Mental Health Study: a double-blind, randomized controlled trial
    Mozurkewich, Ellen
    Clinton, Chelsea
    Chilimigras, Julie
    Hamilton, Susan
    Allbaugh, Lucy
    Berman, Deborah
    Marcus, Sheila
    Vazquez, Delia
    Romero, Vivian
    Treadwell, Marjorie
    Keeton, Kristie
    Vahratian, Anjel
    Schrader, Ronald
    Djuric, Zora
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S19 - S20
  • [48] The effect of omega-3 fatty acids for depressive symptoms among pregnant women in Japan and Taiwan: a randomized, double-blind, placebo-controlled trial and biomarker study
    Nishi, Daisuke
    Su, Kuan-Pin
    Usuda, Kentaro
    Chang, Jane Pei-Chen
    Hamazaki, Kei
    Ishima, Tamaki
    Hashimoto, Kenji
    Matsuoka, Yutaka J.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2019, 88 : 96 - 97
  • [49] The Beyond Ageing Project Phase 2-a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial
    Cockayne, Nicole L.
    Duffy, Shantel L.
    Bonomally, Rosalind
    English, Amelia
    Amminger, Paul G.
    Mackinnon, Andrew
    Christensen, Helen M.
    Naismith, Sharon L.
    Hickie, Ian B.
    TRIALS, 2015, 16
  • [50] Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study
    Belanger, Stacey Ageranioti
    Vanasse, Michel
    Spahis, Schohraya
    Sylvestre, Marie-Pierre
    Lippe, Sarah
    l'Heureux, Francois
    Ghadirian, Parviz
    Vanasse, Catherine-Marie
    Levy, Emile
    PAEDIATRICS & CHILD HEALTH, 2009, 14 (02) : 89 - 98